CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale Director sold 20,000 shares at an average $35.61 ($712,110)
- 4 Option exercise Director acquired 62,500 shares (option exercise)
- 4/A Open-market sale Director sold 20,000 shares at an average $33.83 ($676,583)
- 4 Returned to the company Director returned 60,000 shares (to the company)
- 4 Grant or award Director acquired 5,986 shares (grant or award)
- 4 Grant or award Director acquired 5,986 shares (grant or award)
- 4 Grant or award Director acquired 5,986 shares (grant or award)
- 4 Grant or award Director acquired 5,986 shares (grant or award)
- 4 Grant or award Director acquired 5,986 shares (grant or award)
- 4 Grant or award Director acquired 5,986 shares (grant or award)
- 4 Grant or award Director acquired 5,986 shares (grant or award)
- 4 Grant or award Director acquired 5,986 shares (grant or award)
- 4 Open-market sale Director sold 20,000 shares at an average $33.83 ($676,583)
- 5 Insider Annual Insider Trading Report
- 4 Open-market sale President and CEO sold 9,491 shares at $34.72 ($329,528)
- 4 Open-market sale CFO and Treasurer sold 2,560 shares at $34.69 ($88,806)
- 4 Open-market sale COO and Secretary sold 2,803 shares at $34.68 ($97,208)
- 4 Open-market sale Chief Medical Officer sold 2,918 shares at $34.71 ($101,284)
- 3/A Insider 3/A
- 4 Open-market sale CFO and Treasurer sold 1,296 shares at $37.09 ($48,073)
Page 9 of 22 · 436 filings